Verification Study of Ciclosporin for Atopic Dermatitis

Severe Atopic Dermatitis Clinical Trial

Official title:

Verification Study of Ciclosporin for Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00232076
• Other study ID #: COLO400D1303
• Status: Completed
• Phase: Phase 3
• First received: October 3, 2005
• Last updated: November 1, 2011
• Start date: May 2004

Study information

• Verified date: November 2011
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy and safety of oral OL27-400MEPC 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8 weeks to patients with severe adult atopic dermatitis.

THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. primary completion date: March 2005
• Gender: Both
• Age group: 20 Years to 64 Years

Eligibility

Inclusion Criteria:

• Appropriate the definition/diagnosis criteria of atopic dermatitis of the Japanese Dermatological Association

• Patients with severest atopic dermatitis [according to the "Guidelines for Treatment of Atopic Dermatitis 2002, the severity of atopic dermatitis will be classified as severest when an eruption associated with severe inflammation (a lesion associated with erythema, papule, erosion, infiltration, lichenification, etc.) is noted on at least 30% of body surface on the day of subject enrollment].

Exclusion Criteria:

• - Patients who received oral preparations, injections, inhaled preparations and suppositories of steroids or immunosuppressants other than tacrolimus hydrate ointments within 14 days of subject enrollment

• Patients who might receive the oral/injection drugs which are known to enhance nephrotoxicity, increase serum potassium levels, HMG-CoA reductase inhibitors or theophylline during the treatment period.

• Patients who received or are receiving an ultraviolet therapy (PUVA therapy, etc.)

• Patients with hypertension, active infectional disease, gout etc. Other protocol-defined exclusion criteria may apply

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dermatitis
• Dermatitis, Atopic
• Eczema
• Severe Atopic Dermatitis

Intervention

Drug:
• ciclosporin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals